

## Commercial/Healthcare Exchange PA Criteria

*Effective: November 13, 2019*

**Prior Authorization:** Duaklir Pressair

**Products Affected:** Duaklir Pressair (aclidinium and formoterol) powder for inhalation 400 mcg/12 mcg

**Medication Description:** Duaklir Pressair is a breath-actuated multi-dose dry powder inhaler for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Duaklir Pressair is a combination of two bronchodilators, aclidinium and formoterol. Aclidinium is a long-acting antimuscarinic antagonist. It competitively and reversibly inhibits the action of acetylcholine at type 3 muscarinic (M3) receptors in bronchial smooth muscle causing bronchodilation. Formoterol is a long-acting selective beta2-adrenergic receptor agonist. It relaxes bronchial smooth muscle by selective action on beta2 receptors with little effect on heart rate.

**Covered Uses:** Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)

**Exclusion Criteria:**

1. Severe hypersensitivity to milk proteins
2. Relief of acute bronchospasm
3. Treatment of asthma

**Required Medical Information:**

1. Diagnosis
2. Previous therapies tried/failed

**Age Restrictions:** 18 years of age and older

**Prescriber Restrictions:** N/A

**Coverage Duration:** 12 months

**Other Criteria:**

- A. Patient has a diagnosis of Chronic Obstructive Pulmonary Disease (COPD): **AND**
- B. Patient has a documented intolerance to, or treatment failure, of an adequate trial of Anoro Ellipta **AND** Stiolto Respimat.

**References:**

1. Duaklir Pressair [package insert]. Morrisville, NC; Circassia Pharmaceuticals Inc.; March 2019.
2. Aclidinium and Formoterol. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL.
3. "Chronic Obstructive Pulmonary Disease (COPD)." World Health Organization, World Health Organization, 21 Sept. 2017, [www.who.int/respiratory/copd/en/](http://www.who.int/respiratory/copd/en/).
4. COPD: Stages, Causes, Treatment, and More." Healthline, Healthline Media, 29 Mar. 2019, [www.healthline.com/health/copd](http://www.healthline.com/health/copd).

## Policy Revision history

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	11/13/19

Last Res. Date 11/13/19



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.